DK2539366T3 - PROTOFIBRIL-BINDING ANTIBODIES AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR PARKINSON'S DISEASE, DEMENS WITH LEWY BODY AND OTHER ALPHA SYNUCLEINOPATHIES - Google Patents
PROTOFIBRIL-BINDING ANTIBODIES AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR PARKINSON'S DISEASE, DEMENS WITH LEWY BODY AND OTHER ALPHA SYNUCLEINOPATHIES Download PDFInfo
- Publication number
- DK2539366T3 DK2539366T3 DK11713058.3T DK11713058T DK2539366T3 DK 2539366 T3 DK2539366 T3 DK 2539366T3 DK 11713058 T DK11713058 T DK 11713058T DK 2539366 T3 DK2539366 T3 DK 2539366T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- cdr
- seq
- gly
- thr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30863810P | 2010-02-26 | 2010-02-26 | |
| US40626010P | 2010-10-25 | 2010-10-25 | |
| PCT/IB2011/050826 WO2011104696A1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2539366T3 true DK2539366T3 (en) | 2018-02-05 |
Family
ID=44227520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11713058.3T DK2539366T3 (en) | 2010-02-26 | 2011-02-25 | PROTOFIBRIL-BINDING ANTIBODIES AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR PARKINSON'S DISEASE, DEMENS WITH LEWY BODY AND OTHER ALPHA SYNUCLEINOPATHIES |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8632776B2 (https=) |
| EP (1) | EP2539366B1 (https=) |
| JP (1) | JP5894939B2 (https=) |
| CN (3) | CN110655573B (https=) |
| AU (1) | AU2011219414B2 (https=) |
| CA (1) | CA2789963C (https=) |
| CY (1) | CY1120014T1 (https=) |
| DK (1) | DK2539366T3 (https=) |
| ES (1) | ES2661925T3 (https=) |
| HR (1) | HRP20180230T8 (https=) |
| HU (1) | HUE038313T2 (https=) |
| LT (1) | LT2539366T (https=) |
| NO (1) | NO2539366T3 (https=) |
| PL (1) | PL2539366T3 (https=) |
| PT (1) | PT2539366T (https=) |
| RS (1) | RS57029B1 (https=) |
| RU (1) | RU2555526C2 (https=) |
| SI (1) | SI2539366T1 (https=) |
| SM (1) | SMT201800044T1 (https=) |
| WO (1) | WO2011104696A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| CA2789963C (en) | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| SG10201700735PA (en) * | 2012-01-20 | 2017-02-27 | Genzyme Corp | Anti-cxcr3 antibodies |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| CA2924268C (en) | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| EP3166970B1 (en) * | 2014-07-10 | 2021-03-10 | BioArctic AB | Improved a-beta protofibril binding antibodies |
| WO2016040905A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded alpha synuclein protein |
| US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
| US10494425B2 (en) | 2015-02-24 | 2019-12-03 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| EP3091087A1 (en) | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US11327080B2 (en) | 2015-07-21 | 2022-05-10 | BioArctic Neruoscience AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| CA3004494A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columiba | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto |
| US10759837B2 (en) | 2015-11-09 | 2020-09-01 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| WO2017152088A1 (en) | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
| CN109475616B (zh) * | 2016-06-02 | 2022-10-18 | 麦迪穆有限责任公司 | 针对α-突触核蛋白的抗体及其用途 |
| RU2019102746A (ru) | 2016-07-14 | 2020-08-14 | Биоарктик Аб | Белок для транспорта в мозг |
| CN109476729A (zh) | 2016-07-18 | 2019-03-15 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| AR110074A1 (es) | 2016-11-15 | 2019-02-20 | H Lundbeck As | Agentes, usos y métodos para el tratamiento de la sinucleinopatía |
| CN110072888B (zh) | 2016-12-16 | 2023-07-18 | H.隆德贝克有限公司 | 药剂、用途和方法 |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| CA3049110A1 (en) * | 2017-01-06 | 2018-07-12 | Abl Bio Inc. | Anti-.alpha.-syn antibody and use thereof |
| CN110506057B (zh) * | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| EP3612566A4 (en) * | 2017-04-21 | 2021-03-03 | Implicit Bioscience Limited | CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| US11220538B2 (en) | 2017-05-01 | 2022-01-11 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| TW201901153A (zh) | 2017-05-16 | 2019-01-01 | 美商安培恩股份有限公司 | 折疊錯誤之ｔａｕ蛋白的檢測及檢測折疊錯誤之ｔａｕ蛋白的套組 |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| JP7204235B2 (ja) | 2017-08-02 | 2023-01-16 | ストレスマーク・バイオサイエンシーズ・インコーポレイテッド | 活性型α－シヌクレインに結合する抗体 |
| EP3672635A4 (en) * | 2017-08-23 | 2021-05-12 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF |
| RU2657763C1 (ru) * | 2017-09-12 | 2018-06-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики болезни паркинсона |
| EP3725802A4 (en) * | 2017-11-17 | 2021-08-11 | ABL Bio Inc. | Antibodies to alpha-synuclein and uses thereof |
| US12071483B1 (en) | 2017-12-14 | 2024-08-27 | Abl Bio Inc. | Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| ES2955992T3 (es) | 2017-12-19 | 2023-12-11 | Chase Therapeutics Corp | Método para evaluar una sinucleinopatía |
| WO2019121952A1 (en) * | 2017-12-21 | 2019-06-27 | H. Lundbeck A/S | Assay, method and treatment of alpha-synucleinopathies |
| CN109957546A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957547A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| US12583894B2 (en) | 2018-04-04 | 2026-03-24 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of Lewy body disorders |
| TW202003576A (zh) * | 2018-05-10 | 2020-01-16 | 美商艾博視訊有限公司 | 活化cd40之單株抗體及其用途 |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| MX2021000778A (es) | 2018-07-24 | 2021-03-31 | Eisai R&D Man Co Ltd | Metodos de tratamiento y prevencion de la enfermedad de alzheimer. |
| WO2020079113A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| KR20210104094A (ko) * | 2018-12-12 | 2021-08-24 | 우시 바이올로직스 아일랜드 리미티드 | 항-tim-3 항체 및 이의 용도 |
| RU2703430C1 (ru) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| EP3946266A4 (en) * | 2019-03-28 | 2023-07-12 | The Chinese University Of Hong Kong | SUMO PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| CA3136679A1 (en) * | 2019-04-30 | 2020-11-05 | Chase Therapeutics Corporation | Alpha-synuclein assays |
| US20220291240A1 (en) * | 2019-08-27 | 2022-09-15 | The Johns Hopkins University | Biomarkers for neurodegenerative disorders |
| CA3163308A1 (en) | 2019-12-31 | 2021-07-08 | Thomas N. Chase | Kinases as biomarkers for neurodegenerative conditions |
| CN111171152B (zh) * | 2020-01-15 | 2023-04-18 | 吉林医药学院 | Pcsk9抗体及其制备方法和应用 |
| NL2025332B1 (en) | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| BR112022024221A2 (pt) | 2020-06-02 | 2022-12-20 | Arcus Biosciences Inc | Anticorpos para tigit |
| RS66984B1 (sr) * | 2020-06-26 | 2025-07-31 | Bioarctic Ab | Antitela koja vezuju alfa-sinuklein protofibril |
| US20230365665A1 (en) | 2020-09-17 | 2023-11-16 | Qatar Foundation For Education, Science And Community Development | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES |
| EP4367516A1 (en) | 2021-07-09 | 2024-05-15 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| US20240352109A1 (en) | 2021-08-30 | 2024-10-24 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| MX2024009492A (es) | 2022-02-02 | 2024-08-09 | Eisai R&D Man Co Ltd | Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181). |
| JP2023132247A (ja) * | 2022-03-10 | 2023-09-22 | 公立大学法人大阪 | シヌクレイノパシー検出用バイオマーカー及びその利用 |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| CN116589567B (zh) * | 2022-11-30 | 2024-03-19 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
| WO2025245381A1 (en) | 2024-05-23 | 2025-11-27 | The Trustrees Of Dartmouth College | Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues |
| WO2026068513A1 (en) | 2024-09-24 | 2026-04-02 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU754062B2 (en) | 1998-07-03 | 2002-10-31 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US20060018918A1 (en) | 2000-12-27 | 2006-01-26 | Board Of Regents, The University Of Texas System | Production of stabilized conformational isomers of disease associated proteins |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| MXPA06004853A (es) * | 2003-11-07 | 2006-07-06 | Immunex Corp | Anticuerpos que se aglutinan al receptor 4 de interleucina. |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US7553639B2 (en) | 2006-01-31 | 2009-06-30 | Elan Pharma International Limited | Alpha-synuclein kinase |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN101161245B (zh) * | 2007-11-29 | 2011-11-09 | 首都医科大学宣武医院 | 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途 |
| PT2282758T (pt) * | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| CA2789963C (en) | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
-
2011
- 2011-02-25 CA CA2789963A patent/CA2789963C/en active Active
- 2011-02-25 SM SM20180044T patent/SMT201800044T1/it unknown
- 2011-02-25 LT LTEP11713058.3T patent/LT2539366T/lt unknown
- 2011-02-25 ES ES11713058.3T patent/ES2661925T3/es active Active
- 2011-02-25 CN CN201910950804.0A patent/CN110655573B/zh active Active
- 2011-02-25 CN CN201180011363.XA patent/CN102869680B/zh active Active
- 2011-02-25 HU HUE11713058A patent/HUE038313T2/hu unknown
- 2011-02-25 RU RU2012140954/10A patent/RU2555526C2/ru active
- 2011-02-25 US US13/578,710 patent/US8632776B2/en active Active
- 2011-02-25 CN CN201610801424.7A patent/CN106397588B/zh active Active
- 2011-02-25 WO PCT/IB2011/050826 patent/WO2011104696A1/en not_active Ceased
- 2011-02-25 HR HRP20180230TT patent/HRP20180230T8/hr unknown
- 2011-02-25 PL PL11713058T patent/PL2539366T3/pl unknown
- 2011-02-25 SI SI201131419T patent/SI2539366T1/en unknown
- 2011-02-25 JP JP2012554464A patent/JP5894939B2/ja active Active
- 2011-02-25 EP EP11713058.3A patent/EP2539366B1/en active Active
- 2011-02-25 NO NO11713058A patent/NO2539366T3/no unknown
- 2011-02-25 AU AU2011219414A patent/AU2011219414B2/en active Active
- 2011-02-25 PT PT117130583T patent/PT2539366T/pt unknown
- 2011-02-25 RS RS20180129A patent/RS57029B1/sr unknown
- 2011-02-25 DK DK11713058.3T patent/DK2539366T3/en active
-
2013
- 2013-08-01 US US13/957,239 patent/US8859501B2/en active Active
-
2014
- 2014-08-28 US US14/472,036 patent/US8968734B2/en active Active
-
2015
- 2015-02-02 US US14/611,690 patent/US9084832B2/en active Active
-
2018
- 2018-02-05 CY CY20181100140T patent/CY1120014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2539366T3 (en) | PROTOFIBRIL-BINDING ANTIBODIES AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR PARKINSON'S DISEASE, DEMENS WITH LEWY BODY AND OTHER ALPHA SYNUCLEINOPATHIES | |
| JP7159185B2 (ja) | 抗ｐｈｆ－タウ抗体及びその使用 | |
| US10208111B2 (en) | Alpha-synuclein antibodies and uses thereof | |
| BR112020018868A2 (pt) | métodos baseados em anticorpo para detectar e tratar doença de alzheimer | |
| TW201716436A (zh) | 特異性針對過度磷酸化τ蛋白之抗體及其使用方法 | |
| EP2542571A1 (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| JP2023521763A (ja) | 抗ｐｈｆ－タウ抗体及びその使用 | |
| JP2020511963A (ja) | ヒトアルファ−シヌクレインに対する抗体 | |
| JP7197494B2 (ja) | 抗Ｔａｕナノボディ | |
| TW202434629A (zh) | 以抗類澱粉β (ABETA)抗體治療神經病症之方法 | |
| TW201840583A (zh) | 對β－類澱粉肽的初原纖維形式具有特異性的抗體之神經細胞保護作用 | |
| WO2025257415A1 (en) | Anti-alpha-synuclein antibody |